Combination Chemotherapy (RCM Protocol: Response-Oriented Cyclic Multidrug Protocol) For the Acute or Lymphoma Type Adult T-cell Leukemia

References

• Shimoyama M., Ota K., Kikuchi M., Yunoki K., Konda S., Takatsuki K., Ichmaru M., Ogawa M., Kimura I., Tominaga S., Tsugane S., Taguchi H., Minato K., Takenaka T., Tobinai K., Kurita S., Oyama A., Hisano S., Kozuru M., Matsumoto M., Nomura K., Takiguchi T., Sugai S., Yamaguchi K., Hattori T., Kinoshita K., Tajima K., Suemasu K. The Lymphoma Study Group 1981–1983 (1988) Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J. Clin. Oncol., 6: 128–141
   PubMed Web of Science ®Google Scholar
• Makino T., Uozumi K., Shimazaki T., Otsuka M., Kuwazuru Y., Saito T., Utsunomiya A., Hanada S., Hashimoto S. Combination Chemotherapy for adult T-cell leukemia (ATL) using Cyclophosphamide, Vindesine, and Prednisolone (CV'P). J. Jpn. Soc. Cancer Ther. 1988; 23: 2657–2662
   PubMedGoogle Scholar
• Nomura K., Matsumoto M. Clinical features of adult T-cell leukemia in Kagoshima, the southernmost district in Japan—comparison with T-cell lymphoma-. Acta Haematologica Japonica 1981; 44: 14464–1457
   Google Scholar
• Shimamoto Y., Suga K., Shimojo M., Nishimura J., Nawata H., Yamaguchi M. Comparison of CHOP versus VEPA therapy in patients with lymphoma type of adult T-cell leukemia. Leuk. Lymph. 1990; 2: 335–340
   PubMed Web of Science ®Google Scholar
• Lofters W., Campbell M., Gibbs W.N., Cheson B.D. 2′-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 1987; 60: 2605–2608
   PubMed Web of Science ®Google Scholar
• Waldmann T.A., Goldman C.K., Bongiovanni K.F., Sharrow S.O., Davey M.P., Cease K.B., Greenberg S.J., Longo D.L. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72: 1805–1806
   PubMed Web of Science ®Google Scholar
• Edelson R., Berger C., Gasparro F., Jagasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., Plewig G., McKiernan G., Christiansen I., Oster M., Honigsmann H., Wilford H., Kokoschka E., Rehle T., Perez M., Stingl G., Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New Engl, J. Med. 1987; 316: 297–303
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Members of The Lymphoma Study Group (1984–87). 1991 Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma; a report from the lymphoma study group (1984–87). Brit, J. Haematol., 79: 428–437
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977; 50: 481–492
   PubMed Web of Science ®Google Scholar
• Matsumoto M., Nomura K., Matsumoto T., Nishioka K., Hanada S., Furusho H., Kikuchi H., Kato Y., Utsunomiya A., Uematsu T., Iwahashi M., Hashimoto S., Yunoki K. Adult T-cell leukemia-lymphoma in Kagoshima district, southwestern Japan: clinical and hematological characteristics. Jpn. J. Clin. Oncol. 1979; 9: 325–336, suppl.
   Web of Science ®Google Scholar
• Kawano F., Yamaguchi K., Nishimura H., Tsuda H., Takatsuki K. Variation in the clinical courses of adult T-cell leukemia. Cancer 1985; 55: 851–856
   PubMed Web of Science ®Google Scholar
• Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Lymphoma Study Group (1984–1987)., Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk. Res. 1991; 15: 81–90
   PubMed Web of Science ®Google Scholar
• Tsukasaki K., Ikeda S., Murata K., Maeda T., Atogami S., Sohda H., Momita S., Jubashi T., Yamada Y., Mine M., Kamihira S., Tomonaga M. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk. Res 1993; 17: 157–166
   PubMed Web of Science ®Google Scholar
• Tamura K., Okayama A., Koga K., Sagawa K., Seita M., Tachibana N., Tsuda K. Total body irradiation as a primary treatment for adult T-cell leukemia. Jpn. J. Clin. Oncol. 1983; 13: 313–324, suppl. 2
   PubMed Web of Science ®Google Scholar
• Tamura K., Makino S., Araki Y., Imamura T., Seita M. Recombinant interferon beta and gamma in the treatment of adult T-cell leukemia. Cancer 1987; 59: 1059–1062
   PubMed Web of Science ®Google Scholar
• Ohno R., Masaoka T., Shirakawa S., Sakamoto S., Hirano M., Hanada S., Yasunaga K., Yokomaku S., Mitomo Y., Nagai K., Yamada K., Furue H. The MST-16 Study Group. 1993 Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of Bis(2,6-dioxopiperazine). Cancer, 71: 2217–2221
   PubMed Web of Science ®Google Scholar
• Kuwazuru Y., Hanada S., Furukawa T., Yoshimura A., Sumizawa T., Utsunomiya A., Ishihashi K., Saito T., Uozumi K., Maruyama M., Ishizawa M., Arima T., Akiyama S. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990; 76: 2065–2071
   PubMed Web of Science ®Google Scholar
• Graeen J.A., Dawson A.A., Fell L.F., Murray S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Brit, J. Clin. Pharmacol 1980; 9: 511–514
   PubMed Web of Science ®Google Scholar
• Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Goldie J.H., Coldmann A.J., Gudauskas G.A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treutment Reports 1982; 66: 439–449
   PubMedGoogle Scholar
• Shimoyama M., Ota K., Kikuchi M., Yunoki K., Konda S., Takatsuki K., Ichimaru M., Tominaga S., Tsugane S., Minato K., Tobinai K., Oyama A., Hisano S., Matsumoto M., Takiguchi T., Yamaguchi K., Kinoshita K., Tajima K., Suemasu K. The Lymphoma Study Group (1981–1983). 1988 Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J. Clin. Oncol., 6: 1088–1097
   PubMed Web of Science ®Google Scholar
• Kinoshita K., Ikeda S., Yamada Y., Amagasaki T., Momita S., Toriya K., Ichimaru M., Kamihira S. Some clinical aspects of adult T-cell leukemia-lymphoma (ATLL) (1) Duration of survival of adult T-cell leukemia (ATL) and some useful parameters. Jpn. J. Clin. Hematol. 1983; 24: 818–825
   PubMedGoogle Scholar
• Shimamoto Y., Suga K., Nishimura J., Nawata arid H., Yamaguchi M. Major prognostic factors of Japanese patients with lymphoma-type adult T-cell leukemia. Am. J. Hematol. 1990; 35: 232–237
   PubMed Web of Science ®Google Scholar
• Shiraishi N., Akiyama S., Nakagawa M., Kobayashi M., Kuwano M. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res. 1987; 47: 2413–2416
   PubMed Web of Science ®Google Scholar
• Sohue R., Yamauchim T., Miyamura K., Sao H., Tahara T., Yoshikawa H., Yoshikawa S., Morishima Y., Kodera Y. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplantation 1987; 2: 441–444
   PubMed Web of Science ®Google Scholar
• Nagafuji K., Harada M., Teshima T., Eto T., Takamatsu Y., Okamura T., Murakawa M., Akashi K., Nilio Y. Hematopoietic progenitor cells from patients with adult T-cell leukemia-lymphoma are not infected with human T-cell leukemia virus type 1. Blood 1993; 82: 2823–2828
   PubMed Web of Science ®Google Scholar
• Takaue Y. Peripheral blood stem cell autografts in children with lymphoma and acute lymphoblastic leukemia: updated experience. Leuk. Lymph. 1991; 3: 241–256
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T.A., Hanchard B., Cranston B., Fitz Gerald D.J.P., Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 1993; 7: 553–562
   PubMed Web of Science ®Google Scholar
• Saito T., Kreitman R.J., Hanada S., Makino T., Utsunomiya A., Sumizawa T., Arima T., Chang C.N., Hudson D., Pastan I., Akiyama S. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor. Cancer Res 1994; 54: 1059–1064
   PubMed Web of Science ®Google Scholar